Colon Cancer

Protocols
13 protocols meet the specified criteria
Disease Site: Colon
Protocol No. Title
OCR12323 A Phase II/III Trial of Neoadjuvant FOLFOX With Selective Use of Combined Modality Chemoradiation Versus Preoperative Combined Modality Chemoradiation for Locally Advanced Rectal Cancer Patients Undergoing Low Anterior Resection With Total Mesorectal Excision (PROSPECT)
OCR12704 NSABP Patient Registry and Biospecimen Profiling Repository (MPR-1)
OCR13631 Molecular Analysis for Therapy Choice (MATCH)
OCR15033 A Phase 1, open-label study to evaluate the safety, tolerability, and pharmacokinetics of TAS-102 in patients with advanced solid tumors and varying degrees of renal impairment
OCR15092 An Open-Label Study of Rovalpituzumab Tesirine in Subjects with Delta-Like Protein 3-Expressing Advanced Solid Tumors
OCR15212 Assessing the Benefits of PhotoVoice in Pancreatic Cancer and Other Advanced Cancers
OCR15355 A Phase 1 Multicenter, Open-label, Dose-escalation and Dose-expansion Study to Evaluate the Safety, Tolerability, Pharmacokinetics, Immunogenicity, and Antitumor Activity of MEDI9447 Alone and in Combination with MEDI4736 in Adult Subjects with Select Advanced Solid Tumors
OCR15832 A Phase II Study of the Dual Immune Checkpoint Blockade with Durvalumab (MEDI4736) plus Tremelimumab Following Palliative Hypofractionated Radiation in Patients with Microsatellite Stable (MSS) Metastatic Colorectal Cancer Progressing on Chemotherapy
OCR16937 A Phase 1 Study of NLG802 for Adult Patients with Recurrent Advanced Solid Tumors
OCR17028 Colorectal Cancer Metastatic dMMR Immuno-Therapy (COMMIT) Study: A Randomized Phase III Study of mFOLFOX6/Bevacizumab Combination Chemotherapy with or without Atezolizumab or Atezolizumab Monotherapy in the First-Line Treatment of Patients with Deficient DNA Mismatch Repair (dMMR) Metastatic Colorectal Cancer
OCR17279 Phase I Clinical Trial of VX-970 in Combination with the Topoisomerase I Inhibitor Irinotecan in Patients with Advanced Solid Tumors
OCR17388 A Phase 1 Study of Pembrolizumab (MK-3475) in Combination with Recombinant Interleukin-12 in Patients with Solid Tumors
OCR17893 Palliative Care for Elderly Outpatients